CLOs on the Move

Aldevron

www.aldevron.com

 
Aldevron provides contract manufacturing and scientific services. We specialize in plasmid DNA, protein production, and antibody generation. PLASMID DNA PRODUCTION With the successful completion of over 50,000 projects, we have developed unsurpassed expertise in plasmid manufacturing. Using proprietary technology, Aldevron manufactures DNA for a wide range of research, preclinical, clinical, and diagnostic applications (1 mg to 100 g). PROTEIN PRODUCTION Aldevron offers a wide range of protein services including host cell optimization, expression screening, process development, contract production, enzyme and antibody assay design, and more. Proteins produced by Aldevron are used for a wide range of agriculture and biomedical applications ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.aldevron.com
  • 4837 Amber Valley Parkway
    Fargo, ND USA 58104
  • Phone: 701.297.9256

Executives

Name Title Contact Details
Keleigh Pearson
Assistant General Counsel - NABU Profile
Jeff Gold
Chief IP Counsel Profile
Rachel Lei
General Counsel and Corporate Secretary Profile
Kenneth Bonnell
Vice President of Quality and Regulatory Affairs Profile

Similar Companies

Scioto Biosciences

Scioto Biosciences is a preclinical stage biotech company dedicated to innovative research and discovery in the field of microbiome therapeutics.

Inspirion Biosciences

Inspirion Biosciences protects the advancement of science, the safety and security of researchers, and the health of surrounding communities through integrated solutions in risk strategy. Learn more here.

Agenta Biotechnologies

Agenta Biotechnologies is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Willow Industries

Willow Industries Ozone Systems. Mitigate Mold & Bacteria. Willow systems provide clean and effective solutions to cannabis contamination.

Myovant

Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women`s health diseases and other endocrine-related disorders. Myovant`s lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a GnRH receptor antagonist. Myovant is in the process of initiating five international Phase 3 clinical trials for relugolix, two in women with heavy menstrual bleeding associated with uterine fibroids, two in women with endometriosis-associated pain, and one in men with advanced prostate cancer. Myovant is simultaneously developing MVT-602, an analog of kisspeptin, for the treatment of female infertility as part of assisted reproduction. Over time, the company intends to expand its development pipeline to include other potential treatments for women`s health and endocrine-related disorders.